Type 2 Diabetes
Conditions
Brief summary
This study is a randomized, open labelled, placebo-controlled clinical trial. The main purpose is to verify the superior effect of gut microbiota directed diet intervention over standard diet intervention by evaluating the changes of HbA1c relative to baseline at 16 weeks and 28 weeks of follow-up.
Interventions
DIETARY_SUPPLEMENTFood
Food
Sponsors
Qilu Hospital of Shandong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed type 2 diabetes mellitus patients who have been diagnosed or screened for treatment without any hypoglycemic drugs; * 6.5%≤HbA1c≤8.5%； * FPG\<10.0mmol/L; * BMI≥24；
Exclusion criteria
* suspected other types of diabetes * Moderate stroke occurred within one year; * Frequent diarrhea or constipation in the past 3 months (more than 4 times / week); * Acute complications occurred in the past 3 months, such as infection, ketosis and acidosis; * Pregnant and lactating women (or women who are currently trying to conceive, or who are likely to have children and do not use contraceptives); * Drinking (1 weeks of drinking more than 5 times, on average 2 two Baijiu or half Jin of yellow wine or 5 bottles of beer above); * Those who have received drug treatment for the following diseases in the past three months: cholecystitis, peptic ulcer, urinary tract infection, acute pyelonephritis, cystitis, hyperthyroidism and other thyroid dysfunction; * Gastrointestinal surgery (except appendicitis and hernia surgery); * Antibiotics have been used in the past 3 months for 3 days or more; * Physical methods, such as liposuction or gastrointestinal reconstruction, have been used to lose weight in the past 3 months; * Physical disability, or inability to take care of themselves, recall and answer questions clearly due to other reasons; * Anemia: hemoglobin \< 10g / dl; * Patients with severe liver diseases such as chronic hepatitis, persistent hepatitis and cirrhosis, and hepatitis B virus surface antigen (HBsAg) positive and abnormal liver function (serum alanine aminotransferase and aspartate aminotransferase are 2.5 times the normal value). * Other serious diseases, such as malignant tumors, serious mental diseases, serious infectious diseases, etc; * Patients who are participating in other intervention studies; * In the judgment of the study physician, there are any conditions that affect the study compliance, such as:Alcohol or drug abuse in the past 12 months; Serious adverse drug treatment compliance in the past 12 months; The residence is far away from the research center, or it is planned to move far away or travel frequently in the next year; The clinical diagnosis of dementia or the judgment of cognitive function by the research physician will affect the research compliance; Other medical, psychological or behavioral factors that affect the study compliance are judged by the study physician.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| changes of HbA1c compared with baseline | 28 weeks | changes of HbA1c compared with baseline |
| remission rate | 28 weeks | remission rate of T2D by ADA guideline；ratio of subjects whose blood glucose can reach completely normal without drug intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| control rate | at 16 weeks of treatment and 28 weeks of follow-up | Proportion of subjects with HbA1c \< 7.0% |
| blood lipid profile | at 16 weeks of treatment and 28 weeks of follow-up | Changes of blood lipids (total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol) relative to baseline |
Countries
China
Contacts
Primary ContactRuxing Zhao, doctor
Backup ContactJianjun Sun, BS
Outcome results
None listed